Gilead Sciences, Inc.

Gilead Sciences, Inc. is an American research-based biopharmaceutical company dedicated to discovering, developing, and commercializing innovative medicines for life-threatening diseases. Headquartered in Foster City, California, the company's mission is to deliver transformative therapeutics that create a healthier world for all people.

Historically, Gilead has been a leader in antiviral therapies, particularly for HIV/AIDS, viral hepatitis (B and C), and influenza, including its significant contributions to COVID-19 treatments. Key products include HIV treatments like Biktarvy, Descovy, and Truvada, hepatitis therapies such as Epclusa and Harvoni, and the COVID-19 antiviral Veklury. In recent years, Gilead has strategically expanded its focus into oncology and inflammation, developing products like Yescarta, Tecartus, and Trodelvy for various cancers.

Led by Chairman and CEO Daniel O'Day, Gilead continues to advance its robust pipeline, which included 58 clinical-stage programs as of April 2025. Recent notable developments include the FDA's acceptance and priority review of a new once-daily HIV regimen (bictegravir plus lenacapavir) in April 2026, and the completion of the acquisition of Arcellx, enhancing its multiple myeloma CAR T cell therapy program. The company also received FDA approval for Yeztugo (lenacapavir), a twice-yearly injectable for HIV prevention, in 2025 and is investing $11 billion through 2030 to strengthen its U.S. manufacturing and R&D capabilities. Gilead aims to deliver over 10 transformative therapies by 2030, reinforcing its market position in critical therapeutic areas.